Patients’ Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing

Abstract

PURPOSE Germline CDH1 pathogenic variants (PV) are associated with hereditary diffuse gastric cancer and lobular breast cancer. Although prevalence of CDH1 PV is low in the general population, detection of these variants is increasing with the growing use of multigene panel testing. Little is known about the experiences of individuals tested for CDH1 variants in the multigene panel testing era. METHODS Participants recruited from the Prospective Registry of Multiplex Testing completed a cross-sectional self-report survey regarding CDH1 genetic testing experiences, medical management, and psychosocial adaptation. RESULTS Discordance existed in interpretations of CDH1 results; 13.3% of cases had disagreements in variant classifications among commercial laboratories, and 21.4% had disagreements between participant self-report and ClinVar classification. Survey data were available from 57 individuals reporting either PV (n = 16) or variants of uncertain significance (VUS; n = 41). Those with PV were more likely than those with VUS to report receiving a recommendation for prophylactic gastrectomy, although only 40.0% of those with PV received this recommendation. Participants with VUS were less satisfied with their health care providers’ knowledge and reported less CDH1 knowledge, distress, and worry about discrimination. Participants with PV perceived greater breast cancer risks, but similar gastric cancer risks, as those with VUS. CONCLUSION Few individuals with CDH1 PV report receiving recommendations for prophylactic gastrectomy, and no differences in perceived gastric cancer risk were observed based on participants’ CDH1 results, suggesting serious unmet informational needs.

Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta‐analysis

“…Table 1 provides the characteristics of the included studies. Of the included 22 papers,17 reported surgical outcomes, 10,15‐17,19‐21,23‐25,27‐30,32,34,35 including mastectomy, lumpectomy, and oophorectomy, and six reported cancer screening outcomes, 16,17,20,21,27,32 including mammography, breast MRI, TVUS, CA‐125 testing, and colonoscopy. Studies were published between 2011 and 2020 representing data collected between 1995 and 2019.…”

CDH1 Gene Mutation Hereditary Diffuse Gastric Cancer Outcomes: Analysis of a Large Cohort, Systematic Review of Endoscopic Surveillance, and Secondary Cancer Risk Postulation

“…PTG for CDH1 mutation carriers is a potentially lifesaving intervention, however this surgery and its sequelae are not without morbidity or effects on quality of life [ 23 , 68 ]. Postoperative complications, including anastomotic leaks and strictures, have been reported in up to 46% of patients [ 22 , 69 ]. Quality of life has been routinely correlated to postsurgical outcomes, with up to half of patients expressing decisional regret in the first four weeks following surgery, with slow resolution [ 21 , 70 ].…”

How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing

“…Although evidence exists that early diffuse gastric cancer has been identified in such patients who do undergo prophylactic gastrectomy, there is still some uncertainty regarding how best to manage these families. 26,27 Additional Issues…”